SecBot SecBot
SECBOTREPLAY Home › Report › ZNTL

ZNTL · DENALI readout delayed to 1H27

Zentalis Pharmaceuticals, Inc. · 8-K filed Nov 9, 2026 at 16:08 ET

At the news

BEARISHIMPACT 5/10

8-K filed Nov 9, 2026 at 16:08 ET

Zentalis reported Q3 2026 net loss of $28.8M ($0.34 per share), narrower than the $0.52 consensus estimate, with cash of $228.9M providing runway into 1H 2028. The DENALI Part 2 topline readout was pushed to 1H 2027 (from year-end 2026), and management plans to discuss accelerated approval with the FDA in 2027, signaling a delay in the regulatory timeline.

  • Q3 2026 net loss $28.8M ($0.34/share) vs consensus $-0.52, beat on EPS
  • Cash $228.9M as of Sep 30, 2026, including $86.9M net from Aug 2026 follow-on offering of 26.45M shares
  • DENALI Part 2 topline readout delayed from year-end 2026 to 1H 2027
  • Management plans to discuss DENALI data with FDA in 2027 to assess accelerated approval opportunity

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access